_PRIVATE_LIMITED_391923.webp)
Matrix Pharma-Chem (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 M
as on 24-10-2024
- Revenue 19.50%
(FY 2023)
- Profit 535.68%
(FY 2023)
- Ebitda 644.13%
(FY 2023)
- Net Worth 6.29%
(FY 2023)
- Total Assets 3.52%
(FY 2023)
About Matrix Pharma-Chem (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 M.
Vinay Kanodia, Seema Kanodia, Ankit Agarwal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24297TG2010PTC067956
- Company No.
067956
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Apr 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Matrix Pharma-Chem (India)?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinay Kanodia  | Director | 15-Apr-2010 | Current |
| Seema Kanodia | Director | 15-Apr-2010 | Current |
| Ankit Agarwal | Director | 20-Jul-2010 | Current |
| Pankaj Dalmia | Director | 20-Jul-2010 | Current |
Financial Performance of Matrix Pharma-Chem (India).
Matrix Pharma-Chem (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.5% increase. The company also saw a substantial improvement in profitability, with a 535.68% increase in profit. The company's net worth moved up by a moderate rise of 6.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Matrix Pharma-Chem (India)?
In 2023, Matrix Pharma-Chem (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
V Kan Pharma Solutions Private LimitedActive 2 years 2 monthsVinay Kanodia and Seema Kanodia are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Tamilnad Mercantile Bank Limited Creation Date: 22 Mar 2017 | ₹2.00 M | Open |
How Many Employees Work at Matrix Pharma-Chem (India)?
Matrix Pharma-Chem (India) has a workforce of 11 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Matrix Pharma-Chem (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Matrix Pharma-Chem (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
